Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 50.56 Million EUR | -4.9% |
| 2022 | 53.16 Million EUR | 15.53% |
| 2021 | 46.02 Million EUR | -6.04% |
| 2020 | 48.97 Million EUR | 10.0% |
| 2019 | 44.52 Million EUR | 116.98% |
| 2018 | 20.52 Million EUR | 333.91% |
| 2017 | 4.72 Million EUR | -16.55% |
| 2016 | 5.66 Million EUR | 23.17% |
| 2015 | 4.6 Million EUR | 98.07% |
| 2014 | 2.32 Million EUR | 110.0% |
| 2013 | 1.1 Million EUR | -22.77% |
| 2012 | 1.43 Million EUR | 74.22% |
| 2011 | 822.2 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 44.48 Million EUR | 0.0% |
| 2023 FY | 50.56 Million EUR | -4.9% |
| 2023 Q4 | 50.56 Million EUR | 0.0% |
| 2023 Q2 | 54 Million EUR | 0.0% |
| 2022 Q2 | 45.1 Million EUR | 0.0% |
| 2022 FY | 53.16 Million EUR | 15.53% |
| 2022 Q4 | 53.16 Million EUR | 0.0% |
| 2021 Q2 | 50.71 Million EUR | 0.0% |
| 2021 FY | 46.02 Million EUR | -6.04% |
| 2021 Q4 | 46.02 Million EUR | 0.0% |
| 2020 Q2 | 51.83 Million EUR | 0.0% |
| 2020 FY | 48.97 Million EUR | 10.0% |
| 2020 Q4 | 48.97 Million EUR | 0.0% |
| 2019 Q2 | 44.07 Million EUR | 0.0% |
| 2019 FY | 44.52 Million EUR | 116.98% |
| 2019 Q4 | 44.52 Million EUR | 0.0% |
| 2018 FY | 20.52 Million EUR | 333.91% |
| 2018 Q2 | 4.02 Million EUR | 0.0% |
| 2018 Q4 | 20.52 Million EUR | 0.0% |
| 2017 FY | 4.72 Million EUR | -16.55% |
| 2017 Q4 | 4.72 Million EUR | 0.0% |
| 2017 Q2 | 5.16 Million EUR | 0.0% |
| 2016 Q2 | 4.08 Million EUR | 0.0% |
| 2016 FY | 5.66 Million EUR | 23.17% |
| 2016 Q4 | 5.66 Million EUR | 0.0% |
| 2015 FY | 4.6 Million EUR | 98.07% |
| 2015 Q4 | 4.6 Million EUR | 0.0% |
| 2015 Q2 | 4.66 Million EUR | 0.0% |
| 2014 Q4 | 2.32 Million EUR | 0.0% |
| 2014 Q2 | 1.33 Million EUR | 0.0% |
| 2014 FY | 2.32 Million EUR | 110.0% |
| 2013 Q4 | 1.1 Million EUR | 0.0% |
| 2013 Q2 | 1.27 Million EUR | 0.0% |
| 2013 FY | 1.1 Million EUR | -22.77% |
| 2012 FY | 1.43 Million EUR | 74.22% |
| 2012 Q4 | 1.43 Million EUR | 0.0% |
| 2011 FY | 822.2 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1391.593% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 8.833% |
| Adocia SA | 13.08 Million EUR | -286.346% |
| Aelis Farma SA | 4.03 Million EUR | -1152.229% |
| Biophytis S.A. | 8.27 Million EUR | -511.427% |
| Advicenne S.A. | 17.42 Million EUR | -190.187% |
| genOway Société anonyme | 7.23 Million EUR | -599.049% |
| IntegraGen SA | 1.12 Million EUR | -4395.726% |
| Medesis Pharma S.A. | 1.2 Million EUR | -4113.75% |
| Neovacs S.A. | 650 Thousand EUR | -7679.231% |
| NFL Biosciences SA | 62.17 Thousand EUR | -81228.208% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1060.677% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1761.17% |
| Sensorion SA | 2.86 Million EUR | -1662.592% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1287.996% |
| TME Pharma N.V. | 1.16 Million EUR | -4236.621% |
| Valbiotis SA | 6.87 Million EUR | -635.17% |
| TheraVet SA | 1.15 Million EUR | -4259.552% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -461.958% |
| argenx SE | 18.1 Million EUR | -179.283% |
| BioSenic S.A. | 28.16 Million EUR | -79.557% |
| Celyad Oncology SA | 902 Thousand EUR | -5505.876% |
| DBV Technologies S.A. | 13.01 Million USD | -288.406% |
| Galapagos NV | 9.59 Million EUR | -426.938% |
| Genfit S.A. | 70.17 Million EUR | 27.948% |
| GeNeuro SA | 7.73 Million EUR | -553.48% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -855.138% |
| Innate Pharma S.A. | 39.89 Million EUR | -26.752% |
| Inventiva S.A. | 37.4 Million EUR | -35.175% |
| MaaT Pharma SA | 14.07 Million EUR | -259.254% |
| MedinCell S.A. | 58.96 Million EUR | 14.24% |
| Onward Medical N.V. | 16.87 Million EUR | -199.662% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -269.432% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -10.402% |
| Oxurion NV | 12.33 Million EUR | -309.964% |
| Pharming Group N.V. | 155.29 Million EUR | 67.439% |
| Poxel S.A. | 46.9 Million EUR | -7.814% |
| GenSight Biologics S.A. | 18.42 Million EUR | -174.392% |
| Transgene SA | 1.25 Million EUR | -3922.673% |
| Financière de Tubize SA | 79.2 Million EUR | 36.155% |
| UCB SA | 3.03 Billion EUR | 98.336% |
| Valneva SE | 208.81 Million EUR | 75.785% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -132965.789% |